Ocean Biomedical (NASDAQ: OCEA) Extends Patent Rights for Breakthrough Idiopathic Pulmonary Fibrosis Discovery To Europe
23. Juni 2023 08:01 ET
|
Ocean Biomedical, Inc.
Patent notice extends global coverage for breakthrough discovery, with potential for treating Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases, including Scleroderma, Nonalcoholic...
Ocean Biomedical (NASDAQ: OCEA) Announces Share Price Target Increase to $17.63 by Fundamental Research Corp. on Positive Results from Independent Study Showing Glioblastoma Tumor Suppression, Received Patents, and Recent Financing
21. Juni 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, June 21, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: “OCEA”), a next-generation biopharma company working to accelerate the development and commercialization of...
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Malaria Vaccine Patent Granted in Brazil, the 25th Patent Allowance for Programs in Infectious Disease, Cancer and Fibrosis
08. Juni 2023 08:01 ET
|
Ocean Biomedical, Inc.
Patent for breakthrough approach to disrupting the malaria parasite’s life cycle adds to a growing global patent portfolio, with 25 patents issued and an additional 38 patents pending. ...
Ocean Biomedical (NASDAQ: OCEA) Announces Initiation of Coverage by Taglich Brothers with a Share Price Target of $20.
01. Juni 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, June 01, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a new-era biopharma company working to accelerate the development and commercialization of scientifically...
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Addition to the Russell 2000® Index
25. Mai 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, May 25, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) announced today that it is expected to be added to the Russell 2000® Index, effective after the U.S. market opens on...
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Award for Novel Cancer Immunotherapy Treatment, Granted for Prostate Cancer, Colon Cancer, Ovarian Cancer, Kidney Cancer, Breast Cancer, Glioblastoma, Melanoma, and Lung Cancer.
23. Mai 2023 08:01 ET
|
Ocean Biomedical, Inc.
Latest patent broadens protection around OCEA’s platform of first-in-class anti-CHi3L1 therapeutic immunotherapy candidates, based on the breakthrough discovery by scientific co-founder, Dr. Jack A....
Ocean Biomedical, Inc. Enters into a $25 Million Convertible Note Facility
16. Mai 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, May 16, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling...
Ocean Biomedical (NASDAQ: OCEA) Announces 70% Increase in Price Target by EF Hutton from $10 to $17 on New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody
01. Mai 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, May 01, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling...
Ocean Biomedical (NASDAQ: OCEA) Announces New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody
27. April 2023 08:01 ET
|
Ocean Biomedical, Inc.
Results published in peer-reviewed Cancer Research share novel insights into Chi3L1’s role in modulating Glioma stem cells and reinforces the potential therapeutic impact of Anti-Chi3L1 Providence,...
Ocean Biomedical (NASDAQ: OCEA) on World Malaria Day Announces Sharing of New Malaria Vaccine Paradigm at PATH Malaria Research Retreat in Washington, DC, by Scientific Co-founder Dr. Jonathan Kurtis
25. April 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, April 25, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling assets from leading research...